A multicenter, randomized controlled study on the efficacy of agomelatine in ameliorating anhedonia, reduced motivation, and circadian rhythm disruptions in patients with major depressive disorder (MDD)

Table 4 Common adverse reactions during treatment in both groups

Adverse Reactions During Treatment	SSRI_S Group (n = 90)	Agomelatine Group (n = 90)	χ² Value	P
Nausea or Vomiting	12 (13.3)	7 (7.8)	1.471	0.225
Headache or Dizziness	10 (11.1)	8 (8.9)	0.247	0.619
Anxiety or Agitation	9 (10.0)	7 (7.8)	0.274	0.600
Sleep Disturbances	8 (8.9)	5 (5.6)	0.746	0.388
Sweating	8 (8.9)	3 (3.3)	2.421	0.120
Palpitations	8 (8.9)	4 (4.4)	2.429	0.232
Sexual Dysfunction	8 (8.9)	1 (1.1)^*	5.713	0.017
Weight Gain	7 (7.8)	1 (1.1)^*	4.709	0.030
Diarrhea or Constipation	5 (5.6)	3 (3.3)	0.131	0.718
Liver Function Abnormalities	4 (4.4)	6 (6.7)	0.424	0.515
Tremor or Muscle Twitching	3 (3.3)	1 (1.1)	0.256	0.613
Total	15 (16.7)	13 (14.4)	0.169	0.681

SSRIs denote Selective Serotonin Reuptake Inhibitors; * represents the comparison between the Agomelatine group and the SSRIs group, P < 0.05

ISSN: 1744-859X